Catherine Marti, MD
Advanced Heart Failure and Transplant Cardiology · Athens, GANPI 1124203989
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $273,105 of the $343,402 with a category attached, or 79.5%. 29 manufacturers reported payments, led by AstraZeneca at 32.1% of the total. Among advanced heart failure and transplant cardiology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 554 payments — averaging $619.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$110K
- Pfizer$92K
- Novartis$56K
- Merck$43K
- Boehringer Ingelheim$17K
- Bayer$10K
- plus $16K from 23 others
Across 62 payments — averaging $4976.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$166K
- Endotronix, Inc.$124K
- American Regent$18K
- Amgen$812
What the payments were for
- Consulting fees$44,65213%
- Speaking & faculty fees$273,10580%
- Travel & lodging$15,1104%
- Food & beverage$10,4033%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 105 | $110,092 |
| Pfizer(2 entities) | 80 | $92,343 |
| Novartis | 157 | $55,743 |
| Merck | 45 | $42,548 |
| Boehringer Ingelheim | 24 | $16,820 |
| Bayer | 4 | $9,634 |
| Abbott | 50 | $6,567 |
| Lilly USA, LLC | 4 | $4,050 |
| Lexicon Pharmaceuticals, Inc. | 9 | $3,216 |
| Cvrx, Inc. | 9 | $600 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $268 |
| Amgen | 10 | $252 |
| E.r. Squibb & Sons, L.L.C. | 10 | $179 |
| Briohealth Solutions, Inc. | 1 | $154 |
| Heartflow, Inc. | 2 | $145 |
| Biotronik Inc. | 1 | $135 |
| Alnylam Pharmaceuticals Inc. | 6 | $124 |
| Medtronic | 1 | $122 |
| Endotronix, Inc. | 1 | $100 |
| Johnson & Johnson | 5 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Boston Scientific | 2 | $30 |
| Edwards Lifesciences | 1 | $23 |
| Atricure, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $17 |
| Argon Medical Devices, Inc. | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| Akcea Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$86,991
- VERQUVO$55,260
- ENTRESTO$54,059
- FARXIGA$50,485
- WAINUA$26,588
- LOKELMA$19,396
- JARDIANCE$19,350
- Kerendia$9,620
- VYNDAMAX$4,536
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,845
- Inpefa$3,120
- HeartMate 3 Left Ventricular Dev$910
- CARDIOMEMS$660
- Barostim Neo System$386
- BRIOVAD$154
- PK Papyrus$135
- Orsiro Mission$135
- HeartMate$130
- FFRct$124
- CoreValve Evolut$122
How this compares
$343,402 in reported general payments places this provider in the 95th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
See all advanced heart failure and transplant cardiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 49 | $2,192,219 |
| EntrestoSacubitril/Valsartan | 774 | $1,018,956 |
| FarxigaDapagliflozin Propanediol | 606 | $733,222 |
| VyndaqelTafamidis Meglumine | 28 | $621,905 |
| EliquisApixaban | 444 | $467,325 |
| JardianceEmpagliflozin | 338 | $402,404 |
| XareltoRivaroxaban | 107 | $125,967 |
| VerquvoVericiguat | 74 | $109,580 |
| Repatha SureclickEvolocumab | 63 | $62,799 |
| Eplerenone | 177 | $16,978 |
| BrilintaTicagrelor | 19 | $14,702 |
| Metoprolol Succinate | 744 | $10,216 |
| Torsemide | 351 | $7,929 |
| DapagliflozinDapagliflozin Propanediol | 14 | $6,358 |
| Spironolactone | 706 | $4,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $92,343 | $3,281,449521 claims |
| NovartisEntresto | $55,743 | $1,018,956774 claims |
| AstraZenecaFarxiga, Brilinta | $110,092 | $747,925625 claims |
| Boehringer IngelheimJardiance | $16,820 | $402,404338 claims |
| Johnson & JohnsonXarelto | $75 | $125,967107 claims |
| MerckVerquvo | $42,548 | $109,58074 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
Other advanced heart failure and transplant cardiology in Athens
- Andrew DarlingtonFayetteville$1M
- Darshak KariaAugusta$296K
- Ugochukwu EgolumGainesville$235K
- Abdul Latif BikakMarietta$214K
- Robert ColeAtlanta$213K
- Nikolas KrishnaMarietta$124K
- Brian HowardMarietta$99K
- Alanna MorrisGainesville$85K
- Rahul LounganiAtlanta$51K
- Evan HinerGainesville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.